Skip to content

Comorbid Esophageal Disorders in IBS Patients

Comorbid Disorders of the Esophagus in Patients With Irritable Bowel Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04759378
Enrollment
50
Registered
2021-02-18
Start date
2021-02-25
Completion date
2021-10-01
Last updated
2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Esophageal Disorders, GERD, Irritable Bowel Syndrome, Non-erosive Reflux Disease

Brief summary

assess the incidence of the entire spectrum of esophageal disorders and possible theories for overlap in IBS patients using different diagnostic modalities.

Detailed description

In the practice of a gastroenterologist, irritable bowel syndrome (IBS) is the most frequent functional disorder. Its prevalence in the population is 9.8%-12.8%. Its frequency in women is more than men. In some studies, it has been shown that a patient may have an overlap of symptoms of different functional diseases of the gastrointestinal tract. Different researchers have ambiguously assessed the frequency of occurrence of esophageal disorders in patients with IBS. So, based on the publications of different authors, they are found in 15-80% of cases. In a study by N. de Bortoli et al. (2016) noted the association of IBS with functional heartburn in 77% of cases, and with GERD and hypersensitive esophagus (called heartburn associated with reflux) - in 33% of cases. Traditionally, diagnostics of a combination of functional disorders of the esophagus and intestines were based on data X-ray and endoscopic methods. However modern research has shown the importance of using in this group of patients with daily combined pH impedance measurement. Thus, many authors have noted the undoubted advantages of this method in the diagnosis of esophageal disorders. Unfortunately, works devoted to this topic, extremely few in number, and the information obtained in them is quite contradictory, which indicates the need to continue research in this direction.

Interventions

DIAGNOSTIC_TESTUpper endoscopy, esophageal manometry, 24-hour pH monitoring

upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Established diagnosis of IBS (according to the Rome criteria of the III revision). * Upper GIT symptoms in the form of heartburn (sometimes belching), a lump in the throat, and non-cardiac chest pain.

Exclusion criteria

* History of thoracic, esophageal, or gastric surgery. * Presence of duodenal or gastric ulcer on upper endoscopy. * Presence of duodenal or gastric cancer on upper endoscopy. * Conditions that prevent the installation of a nasogastric tube (nasopharyngeal formation, severe lumen-facial trauma). * mental disorders state and disability. * Pregnancy and breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of GERD in IBS patients who have upper GIT symptomsbaselineuse the result of the comprehensive examination, upper endoscopy, esophageal manometry, and 24h pH monitoring to reveal that comorbid disorders of the esophagus in patients with IBS.
Incidence of Functional esophageal disorders in IBS patient who have upper GIT symptoms.baselineuse the result of the comprehensive examination, including upper endoscopy, esophageal manometry, and 24h pH monitoring to reveal that comorbid disorders of the esophagus in patients with IBS.

Contacts

Primary Contactbishoy s shehata, doctor
bishoy.shehata77@gmail.com+201271724586
Backup Contacthossam m Abdelwahaab, Lecturer
h.mahmoud@aun.edu.eg+201271724586

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026